The ProWide study has finally been published.
In a Danish population, remote ePRO-based symptom monitoring does not improve survival for patients with #lungcancer.
Should we reevaluate the expected clinical benefits of ePROs? @JCOOP_ASCO
https://t.co/80IKDW1LWT @cancer_dk
Editorial comments on the ProWide study. I agree that clinical use of ePROs offers several important benefits beyond overall survival. #lungcancer https://t.co/4BfE0k4TxY
I don't think I've ever worked this hard on anything in my career.
The initial work for this study started back in 2016. Despite legal challenges with digital health data and the COVID-19 lockdown, we succeeded with a tremendous collaboratory effort in this Danish national RCT 🙂
Remote Symptom Monitoring of Patients With Advanced
Lung Cancer (The ProWide Study): A Randomized
Controlled Trial https://t.co/9PIiEj60zj
Authored by @rbfriis et al. #LungCancer#lcsm
Man bør anerkende, at der er områder, hvor mænd er særligt udsatte. Ligestillingen halter, når det for eksempel kommer til mænds mentale sundhed. Det har jeg skrevet om sammen med @SamiraNawa og en række aktører på området. #dkpol#sundpol
https://t.co/hfFpgpTQQy
The ProWide study has finally been published.
In a Danish population, remote ePRO-based symptom monitoring does not improve survival for patients with #lungcancer.
Should we reevaluate the expected clinical benefits of ePROs? @JCOOP_ASCO
https://t.co/80IKDW1LWT @cancer_dk
Original Article: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/dcXkj4NQw7
#ESMO24 | @myESMO
Bravo! @ciccarese_c - beautiful presentation. Congrats to you, @DrIacovelli & the stellar team on intriguing data - a hugely important contribution to the emerging data on #microbiome modulation. Looking fwd to seeing next steps! #ESMO24